Cisplatin Dosing for Concurrent Chemoradiation in Head and Neck Cancer
For definitive concurrent chemoradiation in locally advanced head and neck cancer, use cisplatin 100 mg/m² every 3 weeks for a total cumulative dose of at least 200 mg/m² (typically 2-3 cycles). This remains the evidence-based standard regimen with the strongest survival benefit 1.
Definitive Treatment Setting
Standard Regimen (First-Line Choice)
- Cisplatin 100 mg/m² IV every 3 weeks for 2-3 cycles concurrent with radiotherapy
- Target cumulative dose: ≥200 mg/m² 1
- This regimen provides the greatest locoregional control and overall survival benefit compared to radiotherapy alone 1
- When using accelerated radiotherapy (70 Gy in 6 weeks), two cycles of cisplatin 100 mg/m² are equivalent to three cycles with standard 7-week radiotherapy, with improved chemotherapy compliance 1
Alternative for Cisplatin-Ineligible Patients
- Platinum plus 5-fluorouracil is a validated alternative for patients who cannot tolerate high-dose cisplatin 1
- Cetuximab with radiotherapy should be reserved only for patients truly unfit for any platinum-based therapy 1
- Altered fractionation radiotherapy should be considered when using cetuximab 1
Critical Caveat on Weekly Cisplatin
Weekly cisplatin 40 mg/m² is NOT recommended as standard practice for definitive treatment. A head-to-head randomized trial in mainly postoperative patients demonstrated that weekly cisplatin 30 mg/m² was inferior to 3-weekly dosing 1, 2. While weekly cisplatin 40 mg/m² has never been directly compared to the standard regimen in a definitive curative trial, the primary evidence favors 3-weekly high-dose cisplatin 1.
Important nuance: A recent 2026 phase III trial 3 showed non-inferiority of weekly cisplatin 40 mg/m² compared to 100 mg/m² every 3 weeks, with lower toxicity. However, this contradicts established guideline recommendations from 2020 1 and 2017 2. Given the priority on guidelines and the fact that this single recent trial contradicts longstanding evidence-based practice, the standard 3-weekly regimen remains the recommended approach until guidelines are updated to incorporate this new data.
Postoperative (Adjuvant) Setting
High-Risk Features (Positive Margins and/or Extracapsular Extension)
- Concurrent high-dose intermittent cisplatin (100 mg/m² every 3 weeks) with postoperative radiotherapy is the strong recommendation 2
- This applies regardless of HPV status or extent of extranodal tumor 2
When High-Dose Cisplatin is Inappropriate
- Weekly cisplatin may be used after careful discussion of patient preferences and limited supporting evidence 2
- For patients unable to receive any cisplatin: radiotherapy alone is preferred over non-cisplatin alternatives 2
- Do NOT use: weekly carboplatin, cetuximab (alone or with chemotherapy), weekly docetaxel, or mitomycin-C 2
- Do NOT use: sequential or adjuvant-only chemotherapy without concurrent radiotherapy 2
Administration Requirements (Per FDA Label)
Preparation and Infusion
- Administer by slow IV infusion over 6-8 hours 4
- Never give by rapid IV injection 4
- Dilute in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g mannitol 4
- Do not use aluminum-containing needles or IV sets (causes precipitation and loss of potency) 4
Hydration Protocol
- Pre-treatment: 1-2 liters of fluid infused 8-12 hours before cisplatin 4
- Post-treatment: Maintain adequate hydration and urinary output for 24 hours 4
Safety Monitoring Before Each Cycle
- Serum creatinine must be <1.5 mg/dL 4
- BUN must be <25 mg/dL 4
- Platelets ≥100,000/mm³ 4
- WBC ≥4,000/mm³ 4
- Audiometric analysis confirming normal auditory acuity 4
Common Pitfalls to Avoid
Overdosing alert: The FDA label specifically warns pharmacists to contact prescribers if dose exceeds 100 mg/m² per cycle 4
Weekly dosing confusion: Do not assume weekly cisplatin is equivalent to 3-weekly dosing based on cumulative dose calculations—the evidence shows different efficacy profiles 1, 2
Cetuximab substitution: Recent trials in HPV-positive oropharyngeal cancer showed cetuximab resulted in shorter overall survival compared to cisplatin, with no reduction in toxicity 1—do not use cetuximab as a routine substitute
Adding cetuximab to cisplatin: This combination does NOT improve outcomes and should not be used 1
Induction chemotherapy: For non-laryngeal/hypopharyngeal tumors, induction chemotherapy followed by concurrent chemoradiation has not shown superiority over concurrent chemoradiation alone 1